$Successful treatment by deucravacitinib of psoriasis refractory to apremilast$

Successful treatment by deucravacitinib of psoriasis refractory to apremilast

Saved in:

Bibliographic Details
Main Authors:	Shigeki Inui, Yukinobu Nakagawa, Manabu Fujimoto
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Journal of Cutaneous Immunology and Allergy
Subjects:	psoriasis vulgaris deucravacitinib apremilast secondary failure PDE4
Online Access:	https://www.frontierspartnerships.org/articles/10.3389/jcia.2025.14639/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adverse Events Associated with Apremilast and Deucravacitinib for Psoriasis: A Pharmacovigilance Study Based on the FAERS Database
by: Xu Y, et al.
Published: (2025-05-01)

Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis
by: David A. De Luca, et al.
Published: (2024-12-01)

Successful Psoriasis Management With Deucravacitinib After Guselkumab‐Associated Eosinophilic Pneumonia
by: Katie K. Lovell, et al.
Published: (2025-06-01)

Assessing the Effect of Apremilast on Serum Leptin levels in Obese Patients with Psoriasis
by: Haitham Mohammed Saad, et al.
Published: (2024-12-01)

Case Report: Effectiveness of deucravacitinib in chronic recurrent multifocal osteomyelitis and concomitant psoriasis
by: Caroline Glatzel, et al.
Published: (2025-05-01)

Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan
by: Teppei Hagino, et al.
Published: (2024-12-01)

Efficacy and Safety of Apremilast in Oncological Patients with Moderate-to-Severe Plaque Psoriasis: A 5 years Retrospective Observational Study
by: Lanna C, et al.
Published: (2025-05-01)

Clinical experience with apremilast for psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2018-09-01)

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
by: Neil J. Korman, et al.
Published: (2024-12-01)

Expression dynamics of cytokine genes is related to the apremilast treatment effectiveness in patients with severe psoriasis
by: Dmitry A. Verbenko, et al.
Published: (2024-03-01)

Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial
by: Ian M. Catlett, et al.
Published: (2024-09-01)

Delayed lichenoid drug eruption associated with apremilast
by: Betty Hinderks-Davis, MD, et al.
Published: (2025-05-01)

A Comparative Study on Efficacy and Safety of Methotrexate Versus Apremilast in the Management of Chronic Plaque Psoriasis: Tertiary Care Center Based Interventional Study
by: Alisha Aryal, et al.
Published: (2024-10-01)

A Comparative Study on Efficacy and Safety of Methotrexate Versus Apremilast in the Management of Chronic Plaque Psoriasis: Tertiary Care Center Based Interventional Study
by: Alisha Aryal, et al.
Published: (2024-10-01)

Generalized granuloma annulare successfully treated with deucravacitinib (Sotyktu)
by: Tatiana Lapa, MD, MSc, et al.
Published: (2025-06-01)

Initiation of apremilast treatment decreases prescribed topical therapy amount in patients with psoriasis: a health insurance claims study in Japan
by: Siddharth Chaudhari, et al.
Published: (2025-12-01)

High Systemic Disease Risk and Therapeutic Delays in Plaque Psoriasis: A Retrospective Analysis of Apremilast Use in the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
by: Kave Shams, et al.
Published: (2025-03-01)

Dual‐Action Psoriasis Therapy: Antiproliferative and Immunomodulatory Effects via Self‐Locking Microneedles
by: Zi Yi Wang, et al.
Published: (2024-12-01)

Research progress on phosphodiesterase 4 inhibitors in the treatment of palmoplantar pustulosis
by: YAO Xinyi, et al.
Published: (2024-11-01)

Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life
by: Matthias Augustin, et al.
Published: (2025-05-01)

Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient
by: Haitham M. Saad, et al.
Published: (2024-12-01)

New opportunities in the treatment of psoriasis and psoriatic arthritis
by: A. A. Kubanov, et al.
Published: (2019-01-01)

Successful treatment of recalcitrant amyopathic dermatomyositis with deucravacitinib in addition to intravenous immunoglobulin
by: Megan E. McNamara, PhD, et al.
Published: (2025-08-01)

New Therapies in the Biological Treatment of Psoriasis: A Review
by: Mateusz Kamil Ożóg, et al.
Published: (2025-06-01)

Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials
by: April W. Armstrong, et al.
Published: (2025-03-01)

Deucravacitinib Improved Interstitial Pneumonia Along with KL-6 Reduction in a Patient with Psoriasis: A Case Report
by: Mima Y, et al.
Published: (2025-07-01)

The efficacy of apremilast in pemphigus: a systematic review of case reports
by: Roudin Hussain Alhasawi, et al.
Published: (2025-05-01)

PDE4 Inhibition Reduced Osteoclast Differentiation in Psoriatic Patients
by: Annunziata Raimondo, et al.
Published: (2025-03-01)

Vulgar Psoriasis Triggered by Active Pulmonary Tuberculosis: A Case Report and Literature Review Highlighting Immunological Interactions and Genetic Susceptibility
by: Alexandra-Cristiana Gache, et al.
Published: (2025-03-01)

APREMILAST: AN UPDATE ON ITS EFFICACY AND SAFETY DURING LONG-TERM TREATMENT OF PATIENTS WITH PSORIATIC ARTHRITIS
by: Yu. L. Korsakova, et al.
Published: (2018-11-01)

THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS
by: Yu. L. Korsakova, et al.
Published: (2016-12-01)

Distinct Impact of Phosphodiesterade-4 (PDE4) Inhibition in Two Pre-clinical Psoriasis Models
by: Sören Dräger, et al.
Published: (2025-04-01)

Apremilast Cocrystals with Phenolic Coformers
by: Yelizaveta Naumkina, et al.
Published: (2024-12-01)

The efficacy and safety of apremilast in patients with psoriatic arthritis concurrent with comorbidity in clinical practice
by: E. Yu. Loginova, et al.
Published: (2019-07-01)

Apremilast treatment of immune-mediated inflammatory skin diseases: a narrative review
by: Xiaoqian Liang, et al.
Published: (2025-08-01)

Refractory ulcers of both legs with psoriasis vulgaris successfully treated with dehydrated human amnion/chorion membrane: A case report
by: Soma Nakaso, et al.
Published: (2025-06-01)

Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States
by: Sang Hee Park, et al.
Published: (2024-12-01)

Apremilast Coadministered with Secukinumab for Effective Treatment of Acrodermatitis Continua of Hallopeau: A Case Report
by: Yao XY, et al.
Published: (2025-05-01)

Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
by: Saurabh Bhatia
Published: (2022-09-01)

Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
by: Saurabh Bhatia
Published: (2022-09-01)